Here’s some other vaccine news of note for the week. More: News of Note—GlaxoSmithKline's Shingrix, Seqirus expansion and more Source: fierce
read moreTeva’s Yitzhak Peterburg is going the way many of his former colleagues have gone in recent months. On Tuesday, Reuters reported that Peterburg, who previously held the company’s chairman and interim CEO position, had resigned from the Israeli drugmaker’s board,
read moreSome of Shire’s investors don’t fully grasp the transition the company is currently making, its CEO Flemming Ornskov says. And he acknowledges he could have done more to help them in that department. More: Why are Shire's shares struggling? Some
read moreValeant and former activist partner Bill Ackman may once again be thwarted in their efforts to get insider trading claims against them tossed. More: Insider trading case against Ackman, Valeant approaches trial: report Source: fierce
read moreATLANTA—Merck’s quest to move Keytruda further into blood cancers hit a snag over the summer, but now, it’s back on track. The FDA has accepted the New Jersey drugmaker’s application for the immuno-oncology star in previously treated primary mediastinal large
read moreCoventry, UK-based Medherant has raised £3.8 million in its latest funding round to help further development of its ibuprofen TEPI Patch. More: Medherant raises £3.8 million for transdermal patch Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals